For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
This is a multicenter prospective randomized phase IIa/IIb clinical trial designed to determine the MTD (Maximum Tolerated Dose) of CD24Fc for acute GVHD (Graft Versus Host Disease) prophylaxis.
Mon, 02/01/2016 to Mon, 06/01/2020
Bone Marrow Disease(s):
myelodysplastic syndromes (MDS)
Drug: CD24Fc Drug: Methotrexate Drug: Tacrolimus